Carboplatin + Gemcitabine

DRUG2 trials

Sponsors

AstraZeneca, Sun Yat-sen University

Conditions

Metastatic Urothelial CancerOvarian CancerPlatinum Sensitive Ovarian Cancer (PSOC)Unresectable Locally Advanced Urothelial Cancer

Phase 2

Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Not yet recruitingNCT07776171

Sun Yat-sen UniversityOvarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC)

Start: 2026-09-30End: 2030-05-30Target: 176Updated: 2026-08-20

Phase 3

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

Active, not recruitingNCT03682068

AstraZenecaUnresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer

Start: 2018-09-27End: 2027-06-01Updated: 2026-08-20

Related Papers

A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours

British Journal of Cancer2023-02-1613 citations

A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE).

Journal of Clinical Oncology2021-02-2028 citations

Antibodies to watch in 2020.

2020-01-01328 citations

A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and SOC chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).

Journal of Clinical Oncology2019-05-205 citations

A phase III, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).

Journal of Clinical Oncology2019-03-018 citations